In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies-Reference-Cited by-同舟云学术

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies

Published:2024-03-27 Issue:1 Volume:16 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Mattei Aimee E.¹,Gutierrez Andres H.¹,Seshadri Soorya¹,Tivin Jacob¹,Ardito Matt¹,Rosenberg Amy S.¹,Martin William D.¹,De Groot Anne S.¹

Affiliation:

1. EpiVax, Inc, Providence, RI, USA

Funder

there is no funding associated with the work featured

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2024.2333729

Reference96 articles.

1. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

2. Immunogenicity of protein therapeutics

3. Immunogenicity Assessment for Therapeutic Protein Products. Accessed March 5 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-assessment-therapeutic-protein-products

4. Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity

5. Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods;Frontiers in Pharmacology;2024-08-09

2. New technologies in therapeutic antibody development: The next frontier for treating infectious diseases;Antiviral Research;2024-07

3. Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis;Frontiers in Immunology;2024-05-15